SymBio Pharmaceuticals Limited
4582・Growth Market・Pharmaceuticals
Governance
Company with an Audit and Supervisory Committee. The Board of Directors consists of 6 internal directors and 3 outside directors serving as members of the Audit and Supervisory Committee, totaling 9 members (as of the end of the current fiscal year, the structure was 5 plus 3, totaling 8 members). A Nomination and Compensation Committee chaired by an outside director has been established to ensure transparency in the compensation determination process. An Internal Control Committee, a Compliance Committee, and an Internal Audit Office have been set up, and a Compliance Hotline is also permanently maintained.
Risk Management
Based on the basic risk management policy and related regulations, the Internal Control Committee (chaired by the Executive Officer and CFO) oversees risk management. It shares risk information with each department and conducts day-to-day risk management. In the event of an emergency, an emergency response headquarters headed by the Representative Director and President is established to respond promptly. A framework has been established whereby the status of risk management is reported to the Board of Directors on a regular or as-needed basis.
Shareholder Returns
No annual dividend (zero dividend) for both FY2025 (ending December 2025) and FY2026 (ending December 2026). Amid material uncertainty regarding the going concern assumption, funds are prioritized for research and development activities. No mention of share buybacks.
Dividend Policy
The annual dividend for FY2025 (ending December 2025) is ¥0.00 (no dividend). The forecast for FY2026 (ending December 2026) is also ¥0.00 (no dividend). Given the nature of the research and development-oriented business, funds are prioritized for strengthening the financial structure and for the continuous implementation of research and development activities, and the company does not plan to pay dividends for the time being.
ESG
Under the corporate philosophy of "Co-creation and Symbiosis," the company positions compliance as its basic stance, and promotes the advancement of women as a key initiative based on SDG Goal 5 (Gender Equality). It has set targets of achieving a female employee ratio of 40% or more and a female temporary staff ratio of 50% or more across the company by March 2027 (as of December 2025, these stood at 30% and 33%, respectively). The company implements diverse hiring practices, a 100% childcare leave utilization rate, and harassment prevention training, among other measures. The ratio of women in managerial positions is 28%. No quantitative disclosure regarding climate change is provided.
Last updated: March 24, 2026